I’ve got a query for you today.
Do you know a truly great private biotech out there with outstanding management, super science, ambitious and novel drug development plans, and the resources and backing needed to see the game out to pivotal data?
If you’ve been reading Endpoints News for awhile, you’ll know why I’m asking. Every year for a stretch that now exceeds many of your careers, I’ve been assembling a roster of private — let me emphasize the private part — biotechs that deserve to be specially recognized for their efforts.
The Endpoints 11 has long been my favorite project of the year. We plan to head to the State Room in Boston on the evening of Sept. 26 to publicly celebrate this year’s selection of remarkable and noteworthy companies. Like last year, I’ll be relying on lots of help for this as we navigate the selection process, with Drew Armstrong, Andrew Dunn and Ryan Cross all pitching in, alongside many others on the Endpoints team.
Which brings me back to my query.
If you know a company that fits the bill, here’s the link to submit their name for consideration. We’d like to hear from you, briefly, about what sets them apart.
Of course, there aren’t any guarantees in this business. The more ambitious the venture, the greater the risk. Not every Endpoints 11 company is victorious in the end. Bitter defeats and setbacks are part of the source code of biotech. This is an industry where you can be completely right about trying, and completely wrong when you get the answer back in human data. But it’s a long haul from start to finish in biotech, and the most promising deserve some recognition along the way.
These companies are, after all, the future of biotech.
There are no particular guidelines. This recognition is not limited to Boston or the Bay Area. There are no restrictions on who’s backing the companies. It’s wide open to the best and brightest.
I hope to hear from you soon. The deadline for responding is July 8.